TO CONSULTING AGREEMENT Sample Clauses
TO CONSULTING AGREEMENT. This Amendment No. 5 to Consulting Agreement (“Amendment No. 4”) is made as of February 1, 2021, by and between Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being O▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, Building 1400 West, Suite 14303, Cambridge, MA 02139 (“Company”) and D▇▇▇▇▇▇▇ Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being 9▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ (“D▇▇▇▇▇▇▇”). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between D▇▇▇▇▇▇▇ and the Company dated as of March 13, 2013 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 (“Amendment”), dated as of November 4, 2002 and effective as of January 1, 2002 (the “Effective Date”) is entered into by and between Schrödinger, Inc. (“Schrödinger” or “Company”), a Delaware corporation with an address at ▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇, ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇, and ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ (“Consultant”), an individual with an address at [**].
TO CONSULTING AGREEMENT. THIS AMENDMENT No. 3 TO CONSULTING AGREEMENT (“Amendment No. 3”) is effective as of March 4, 2024 (hereinafter “Effective Date”) by and between BridgeBio Pharma, Inc. (hereinafter “Company”), a Delaware corporation with offices at ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, Suite 250, Palo Alto, California 94304, and ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ (hereinafter “Consultant”), located at [***] (each herein referred to as a “Party” and collectively as “Parties”).
TO CONSULTING AGREEMENT. Dear R▇▇▇▇▇▇: This is in reference to the Consulting Agreement between VL42, d/b/a Omega Therapeutics, Inc., and R▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Ph.D. dated November 7, 2016 (the “Agreement”). All capitalized terms used in this letter and not otherwise defined in this letter shall have the same meaning as in the Agreement.
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is made as of April 30, 2014 (“Effective Date”), by and between D▇▇▇▇▇▇▇ Advisors, LLC (“Consultant”), a corporation located at 9▇ ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ and Vedantra Pharmaceuticals, Inc., a Delaware corporation (“Company”), located at One K▇▇▇▇▇▇ Square, Building 1▇▇▇ ▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇. Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between D▇▇▇▇▇▇▇ Advisors, LLC and the Company dated as of March 13, 2014 (“Agreement”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is entered into by and between AlloVir, Inc. (formerly ViraCyte, Inc.), a Delaware corporation (the “Company”), and ▇▇▇ ▇▇▇▇ (“Consultant”), effective generally as of January 1, 2020 (the “Effective Date”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment”) is made and entered into as of January 10, 2017 (“Amendment Effective Date”) by and between ACUCELA INC., a Washington corporation (“Company”) and ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ (“Consultant”).
TO CONSULTING AGREEMENT. This Amendment No. 1 to Consulting Agreement (“Amendment No. 1”) is made as of January 2, 2013 (“Effective Date”) by and between ▇▇▇▇▇ ▇▇▇▇▇▇ (“Consultant”) and ACUCELA INC. (“Company”).
TO CONSULTING AGREEMENT. Please acknowledge your acceptance of the foregoing Amendment by signing and returning a copy to the undersigned whereupon it shall become a binding agreement between us.
TO CONSULTING AGREEMENT. This Addendum No. 1 to Consulting Agreement (“First Consulting Agreement Addendum”), effective as of October 17, 2011, is incorporated by reference in, appended to and made a part of the Consulting Agreement, dated June 13, 2011 (“Consulting Agreement”), executed by Metro Bank (“Metro”) and ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇.(“Consultant”).